638 Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's DiseaseBrian Bressler, Gerassimos J. Mantzaris, Uri Kopylov et al.|The American Journal of Gastroenterology|2019Cited by 6